Brokerages Set Precision BioSciences, Inc. (NASDAQ:DTIL) Target Price at $32.25

Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $32.25.

Several research firms recently commented on DTIL. Oppenheimer began coverage on shares of Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a research note on Monday, August 3rd. Wall Street Zen downgraded shares of Precision BioSciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th.

Precision BioSciences Trading Down 2.5%

NASDAQ DTIL opened at $6.50 on Thursday. The company has a quick ratio of 12.82, a current ratio of 12.82 and a debt-to-equity ratio of 0.50. Precision BioSciences has a twelve month low of $3.53 and a twelve month high of $9.62. The company has a market cap of $179.40 million, a price-to-earnings ratio of -2.32 and a beta of 1.24. The business’s fifty day moving average is $7.54 and its 200 day moving average is $7.13.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. As a group, sell-side analysts expect that Precision BioSciences will post -3.33 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of DTIL. HBK Sorce Advisory LLC acquired a new position in shares of Precision BioSciences in the fourth quarter worth approximately $38,000. Miller Financial Services LLC increased its position in Precision BioSciences by 50.0% during the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock valued at $62,000 after purchasing an additional 5,000 shares during the period. Quantinno Capital Management LP acquired a new stake in Precision BioSciences during the 1st quarter valued at approximately $104,000. Engineers Gate Manager LP bought a new position in Precision BioSciences during the 2nd quarter worth approximately $164,000. Finally, Bank of America Corp DE raised its holdings in Precision BioSciences by 167.6% during the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after purchasing an additional 17,172 shares during the last quarter. 37.99% of the stock is owned by institutional investors and hedge funds.

Precision BioSciences Company Profile